Interleukin 18 as a Marker of Chronic Nephropathy in Children after Anticancer Treatment
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interleukin 18 as a Marker of Chronic Nephropathy in Children after Anticancer Treatment
Authors
Keywords
-
Journal
DISEASE MARKERS
Volume 35, Issue -, Pages 811-818
Publisher
Hindawi Limited
Online
2013-11-28
DOI
10.1155/2013/369784
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Renal Dysfunction and Elevated Blood Pressure in Long-Term Childhood Cancer Survivors
- (2012) S. L. Knijnenburg et al. Clinical Journal of the American Society of Nephrology
- Hospitalization rates among survivors of childhood cancer in the childhood cancer survivor study cohort
- (2011) Beth A. Kurt et al. PEDIATRIC BLOOD & CANCER
- Combination of urinary kidney injury molecule-1 and interleukin-18 as early biomarker for the diagnosis and progressive assessment of acute kidney injury following cardiopulmonary bypass surgery: a prospective nested case–control study
- (2010) Xin-Ling Liang et al. BIOMARKERS
- Elevated Urinary IL-18 Levels at the Time of ICU Admission Predict Adverse Clinical Outcomes
- (2010) E. D. Siew et al. Clinical Journal of the American Society of Nephrology
- Urinary Biomarkers in the Clinical Prognosis and Early Detection of Acute Kidney Injury
- (2010) J. L. Koyner et al. Clinical Journal of the American Society of Nephrology
- Evolving use of biomarkers for kidney injury in acute care settings
- (2010) Elliot Ho et al. Current Opinion in Critical Care
- Glucarpidase, Leucovorin, and Thymidine for High-Dose Methotrexate-Induced Renal Dysfunction: Clinical and Pharmacologic Factors Affecting Outcome
- (2010) Brigitte C. Widemann et al. JOURNAL OF CLINICAL ONCOLOGY
- Cilastatin Attenuates Cisplatin-Induced Proximal Tubular Cell Damage
- (2010) S. Camano et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects
- (2010) Katherine A Janeway et al. LANCET ONCOLOGY
- Prognostic significance of acute renal injury in acute tumor lysis syndrome
- (2010) Michael Darmon et al. LEUKEMIA & LYMPHOMA
- Clinical Usefulness of Novel Biomarkers for the Detection of Acute Kidney Injury following Elective Cardiac Surgery
- (2010) Miaolin Che et al. NEPHRON CLINICAL PRACTICE
- Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose
- (2010) Roderick Skinner et al. PEDIATRIC BLOOD & CANCER
- Tubular proteinuria in acute kidney injury: a critical evaluation of current status and future promise
- (2010) C. R. Parikh et al. ANNALS OF CLINICAL BIOCHEMISTRY
- Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors
- (2009) Roderick Skinner et al. EUROPEAN JOURNAL OF CANCER
- Renal function in late survivors of Iranian children with cancer: Single centre experience
- (2009) N Hooman et al. INDIAN JOURNAL OF CANCER
- Long-Term Evaluation of Ifosfamide-Related Nephrotoxicity in Children
- (2009) Odile Oberlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers of Acute Kidney Injury
- (2008) Charles L. Edelstein ADVANCES IN CHRONIC KIDNEY DISEASE
- Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia
- (2008) Daniel A. Mulrooney et al. CANCER
- IL-18 Contributes to Renal Damage after Ischemia-Reperfusion
- (2008) H. Wu et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The Future of Pediatric Acute Kidney Injury Management—Biomarkers
- (2008) Prasad Devarajan SEMINARS IN NEPHROLOGY
- Biomarkers—A Potential Route for Improved Diagnosis and Management of Ongoing Renal Damage
- (2008) R. Oberbauer TRANSPLANTATION PROCEEDINGS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started